Peptide research & literature
Sara writes the peptide guides, the mechanism explainers, and the research-literature reviews. Her background is in pharmacology research — eight years at a contract research organization running preclinical pharmacokinetics work before moving into science writing full-time. She reads the primary research literature so vialaudit readers don't have to, and she's the person on the desk who decides which peptide is mature enough for a guide. If a compound only has rodent data, she says so. If a Phase 2 trial is being misrepresented in community discussion, she writes the literature read. Sara writes under a pen name. The peptide research-protocol space attracts strong opinions and direct outreach to authors; she'd rather keep the email volume manageable and the work honest.
Peptide guides, mechanism explainers, primary-literature reviews, pharmacokinetics summaries, dose-research literature, trial result reads.
BPC-157 and TB-500 are the most-stacked combination in research-peptide protocols. The compounds work through different mechanisms — angiogenesis vs actin sequestration — which is why the combination is studied. Here's the literature read.
A literature read of the dose-titration schedules, maintenance doses, and tolerability protocols used in Eli Lilly's published retatrutide trials. Not human-use guidance — the regulatory state in May 2026 is Phase 3, no FDA approval.
A literature read of the side-effect profile from Eli Lilly's published Phase 2 and TRIUMPH Phase 3 retatrutide data — GI events, the heart-rate signal, dose-titration tolerability, and the dimensions still being characterized.
Eli Lilly's Phase 3 retatrutide program reads out across the TRIUMPH-1 through TRIUMPH-5 trials. Here is what the published Phase 3 data shows so far, what it does not show, and what changes if the FDA submission proceeds in 2026.
Tips, corrections, or comments on research desk coverage: research@vialaudit.com
New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.